<DOC>
	<DOCNO>NCT01413048</DOCNO>
	<brief_summary>The purpose study evaluate antihypertensive effect AGSCT101 tablet patient stage 1 2 essential hypertension .</brief_summary>
	<brief_title>Clinical Trial Evaluate Antihypertensive Effect AGSCT101 Patient With Hypertension</brief_title>
	<detailed_description>This study 2,8 week , multi-center , randomize , double-blind , active clinical trial evaluate efficacy safety AGSCT101 versus Carvedilol patient stage 1 2 essential hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Male female outpatient â‰¥ 19 year age Mild moderate essential hypertension : sDBP 90 ~ 109 , sSBP 140 ~ 179 Subjects agree participate sudy give write informed consent Subjects consider understand study , cooperative , able followedup end study The sit DBP 110mmHg sit SBP 180mmHg Patients postural hypotension Patients severe renal ( Creatinine 1.5mg/dl ) , gastrointestinal , hematological hepatic ( AST , ALT 3 time upper limit normal ) disease Female childbearing potential undergo hysterectomy postmenopausal Patients judge history alcohol drug abuse investigator Patients history myocardial infarction , severe coronary artery disease clinically significant heart failure valvular defect last 6 month Patients uncontrolled diabetes mellitus Patients participate clinical trial 12 week Screening Patients judge inappropriate study investigator reason</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Essential Hypertension</keyword>
	<keyword>Hypertension</keyword>
</DOC>